Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

JD. Milosevic Feenstra, H. Nivarthi, H. Gisslinger, E. Leroy, E. Rumi, I. Chachoua, K. Bagienski, B. Kubesova, D. Pietra, B. Gisslinger, C. Milanesi, R. Jäger, D. Chen, T. Berg, M. Schalling, M. Schuster, C. Bock, SN. Constantinescu, M. Cazzola,...

. 2016 ; 127 (3) : 325-32. [pub] 20150930

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020248

Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic diseases characterized by clonal hematopoiesis and hyperproliferation of terminally differentiated myeloid cells. The disease is driven by somatic mutations in exon 9 of CALR or exon 10 of MPL or JAK2-V617F in >90% of the cases, whereas the remaining cases are termed "triple negative." We aimed to identify the disease-causing mutations in the triple-negative cases of ET and PMF by applying whole-exome sequencing (WES) on paired tumor and control samples from 8 patients. We found evidence of clonal hematopoiesis in 5 of 8 studied cases based on clonality analysis and presence of somatic genetic aberrations. WES identified somatic mutations in 3 of 8 cases. We did not detect any novel recurrent somatic mutations. In 3 patients with clonal hematopoiesis analyzed by WES, we identified a somatic MPL-S204P, a germline MPL-V285E mutation, and a germline JAK2-G571S variant. We performed Sanger sequencing of the entire coding region of MPL in 62, and of JAK2 in 49 additional triple-negative cases of ET or PMF. New somatic (T119I, S204F, E230G, Y591D) and 1 germline (R321W) MPL mutation were detected. All of the identified MPL mutations were gain-of-function when analyzed in functional assays. JAK2 variants were identified in 5 of 57 triple-negative cases analyzed by WES and Sanger sequencing combined. We could demonstrate that JAK2-V625F and JAK2-F556V are gain-of-function mutations. Our results suggest that triple-negative cases of ET and PMF do not represent a homogenous disease entity. Cases with polyclonal hematopoiesis might represent hereditary disorders.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020248
003      
CZ-PrNML
005      
20160726094457.0
007      
ta
008      
160722s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2015-07-661835 $2 doi
024    7_
$a 10.1182/blood-2015-07-661835 $2 doi
035    __
$a (PubMed)26423830
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Milosevic Feenstra, Jelena D $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
245    10
$a Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms / $c JD. Milosevic Feenstra, H. Nivarthi, H. Gisslinger, E. Leroy, E. Rumi, I. Chachoua, K. Bagienski, B. Kubesova, D. Pietra, B. Gisslinger, C. Milanesi, R. Jäger, D. Chen, T. Berg, M. Schalling, M. Schuster, C. Bock, SN. Constantinescu, M. Cazzola, R. Kralovics,
520    9_
$a Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic diseases characterized by clonal hematopoiesis and hyperproliferation of terminally differentiated myeloid cells. The disease is driven by somatic mutations in exon 9 of CALR or exon 10 of MPL or JAK2-V617F in >90% of the cases, whereas the remaining cases are termed "triple negative." We aimed to identify the disease-causing mutations in the triple-negative cases of ET and PMF by applying whole-exome sequencing (WES) on paired tumor and control samples from 8 patients. We found evidence of clonal hematopoiesis in 5 of 8 studied cases based on clonality analysis and presence of somatic genetic aberrations. WES identified somatic mutations in 3 of 8 cases. We did not detect any novel recurrent somatic mutations. In 3 patients with clonal hematopoiesis analyzed by WES, we identified a somatic MPL-S204P, a germline MPL-V285E mutation, and a germline JAK2-G571S variant. We performed Sanger sequencing of the entire coding region of MPL in 62, and of JAK2 in 49 additional triple-negative cases of ET or PMF. New somatic (T119I, S204F, E230G, Y591D) and 1 germline (R321W) MPL mutation were detected. All of the identified MPL mutations were gain-of-function when analyzed in functional assays. JAK2 variants were identified in 5 of 57 triple-negative cases analyzed by WES and Sanger sequencing combined. We could demonstrate that JAK2-V625F and JAK2-F556V are gain-of-function mutations. Our results suggest that triple-negative cases of ET and PMF do not represent a homogenous disease entity. Cases with polyclonal hematopoiesis might represent hereditary disorders.
650    _2
$a variabilita počtu kopií segmentů DNA $7 D056915
650    _2
$a mutační analýza DNA $7 D004252
650    12
$a exom $7 D059472
650    _2
$a genomika $x metody $7 D023281
650    12
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a Janus kinasa 2 $x genetika $x metabolismus $7 D053614
650    12
$a mutace $7 D009154
650    _2
$a myeloproliferativní poruchy $x genetika $x metabolismus $7 D009196
650    _2
$a primární myelofibróza $x genetika $x metabolismus $7 D055728
650    _2
$a receptory thrombopoetinu $x genetika $x metabolismus $7 D053628
650    _2
$a esenciální trombocytemie $x genetika $x metabolismus $7 D013920
650    _2
$a inaktivace chromozomu X $x genetika $7 D049951
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nivarthi, Harini $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
700    1_
$a Gisslinger, Heinz $u Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;
700    1_
$a Leroy, Emilie $u Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université Catholique de Louvain, Brussels, Belgium;
700    1_
$a Rumi, Elisa $u Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;
700    1_
$a Chachoua, Ilyas $u Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université Catholique de Louvain, Brussels, Belgium;
700    1_
$a Bagienski, Klaudia $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
700    1_
$a Kubesova, Blanka $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Center of Molecular Biology and Gene Therapy, Department of Internal Medicine-Hematology and Oncology, University Hospital Brno and Medical Faculty Masaryk University, Brno, Czech Republic; and.
700    1_
$a Pietra, Daniela $u Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;
700    1_
$a Gisslinger, Bettina $u Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;
700    1_
$a Milanesi, Chiara $u Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy;
700    1_
$a Jäger, Roland $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
700    1_
$a Chen, Doris $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
700    1_
$a Berg, Tiina $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
700    1_
$a Schalling, Martin $u Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;
700    1_
$a Schuster, Michael $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
700    1_
$a Bock, Christoph $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria;
700    1_
$a Constantinescu, Stefan N $u Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université Catholique de Louvain, Brussels, Belgium;
700    1_
$a Cazzola, Mario $u Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
700    1_
$a Kralovics, Robert $u CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria;
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 127, č. 3 (2016), s. 325-32
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26423830 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160726094717 $b ABA008
999    __
$a ok $b bmc $g 1154918 $s 944776
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 127 $c 3 $d 325-32 $e 20150930 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace